Related Experiment Video
Updated: Aug 18, 2026
Novel Protocol for Generating Physiologic Immunogenic Dendritic Cells
Published on: May 17, 2019
Update on extracorporeal photochemotherapy for graft-versus-host disease treatment
1Unité Bioclinique de Thérapie Cellulaire, CHU Clermont-Ferrand, France. jkanold@chu-clermontferrand.fr
Insights
Extracorporeal photochemotherapy (ECP) effectively treats pediatric graft-versus-host disease (GvHD) with minimal side effects. This therapy allows for reduced or discontinued immunosuppressants in children with acute and chronic GvHD.
Area of Science:
- Pediatric Hematology
- Immunology
- Transplantation
Background:
- Graft-versus-host disease (GvHD) is a significant complication following allogeneic stem cell transplantation.
- Pediatric GvHD management presents unique challenges, requiring effective and safe therapeutic options.
- Limited data exists on extracorporeal photochemotherapy (ECP) for pediatric GvHD.
Purpose of the Study:
- To evaluate the efficacy and safety of ECP in pediatric patients with acute and chronic GvHD.
- To assess the impact of ECP on concomitant immunosuppressive therapy in children.
- To determine ECP's utility in refractory GvHD cases.
Main Methods:
- Retrospective analysis of pediatric patients treated with ECP for GvHD.
- Inclusion of data from Italian and French centers.
- Monitoring of treatment response, side effects, and changes in immunosuppressive drug dosages.
Main Results:
- Improvement observed in 73% of acute GvHD and 63% of chronic GvHD pediatric cases.
- ECP was associated with minimal side effects, even in young patients.
- ECP enabled reduction or discontinuation of immunosuppressive therapy without GvHD exacerbation in responders.
Conclusions:
- ECP is a valuable therapeutic option for pediatric GvHD refractory to conventional treatments.
- ECP demonstrates a favorable safety profile in pediatric patients.
- ECP facilitates a decrease in immunosuppression, improving patient management.
Abstract:
Pediatric experience with extracorporeal photochemotherapy (ECP) for graft-versus-host disease (GvHD) has mainly been reported by Italian and French groups. Data concerning 41 children with acute GvHD and 63 children affected by chronic GvHD are available. In 73 and 63% of them, respectively, improvement was observed, with addition of ECP to their immunosuppressive regimen. Treatment with ECP was associated with minimal side effects, even in the smallest of patients. In all responded pediatric patients, both with acute and chronic GvHD, ECP allowed progressive reduction or discontinuation of the concomitant pharmacological immunosuppressive therapy without an increase in GvHD activity. These data show that ECP is a useful therapy for children affected by GvHD resistant to conventional treatment and can be safely used.
